Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedCap ABSTU:61MA +2.23%80 EBITDA Margin % is 23.05% as of Mar. 2026, which is 13% above its 10-year median of 20.48. GuruFocus rates STU:61MA with a GF Score™ of 80/100 and a GF Value™ of €50.29. Among 816 Medical Devices & Instruments companies, MedCap AB ranks better than 81% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. MedCap AB's EBITDA for the
three
months ended in Mar. 2026 was €11.9 Mil. MedCap AB's Revenue for the
three
months ended in Mar. 2026 was €51.7 Mil. Therefore, MedCap AB's EBITDA margin for the quarter that ended in Mar. 2026 was 23.05%.
MedCap AB (STU:61MA) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
MedCap AB EBITDA Margin % Related Terms
MedCap AB EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for MedCap AB's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:61MA vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, MedCap AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MedCap AB EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MedCap AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where MedCap AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MedCap AB (STU:61MA) has a EBITDA Margin % of 23.05% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on MedCap AB and its competitors. This is 13% above median its historical median of 20.48. Over the past decade, MedCap AB's EBITDA Margin % has ranged from 3.64 to 23.11. According to the industry distribution chart, MedCap AB ranks #155 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 19%.
Is MedCap AB's EBITDA Margin % too high?
MedCap AB's current EBITDA Margin % of 23.05% is 13% above median its 10-year median of 20.48. Over the past 10 years, this metric has ranged from a low of 3.64 to a high of 23.11. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. MedCap AB's value of 23.05% is 208.4% above this industry median. Based on the distribution chart, MedCap AB ranks #155 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, MedCap AB has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does MedCap AB's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, MedCap AB ranks #155 out of 816 companies for EBITDA Margin %. This places MedCap AB in the top 19% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.48. MedCap AB's value of 23.05% is 208.4% above this benchmark. Historically, MedCap AB's own EBITDA Margin % has ranged from 3.64 to 23.11 over the past decade. While the company's 10-year median is 20.48 vs. the industry median of 7.48, MedCap AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MedCap AB's current EBITDA Margin % of 23.05% is 208.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on MedCap AB and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MedCap AB's current EBITDA Margin % is 23.05%, which is 13% above median its own 10-year median of 20.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedCap AB stock overvalued right now?
MedCap AB (STU:61MA) has a current EBITDA Margin % of 23.05%. The stock's GF Value™ is €50.29, compared to a current price of €46.70 — trading 7.1% below its estimated fair value. The current EBITDA Margin % is 23.05%, which is 13% above median its 10-year median of 20.48 and 208.4% above the Medical Devices & Instruments industry median of 7.48. MedCap AB's overall GF Score™ is 80/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For MedCap AB (STU:61MA), the current EBITDA Margin % is 23.05% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MedCap AB (STU:61MA) Overvalued in 2026?
Based on GuruFocus' analysis, MedCap AB stock appears to be undervalued.
The current stock price of €46.70 is trading 7.1% below its estimated GF Value™ of €50.29.
Key valuation signals for STU:61MA:
EBITDA Margin %: 23.05% (13% above median its 10-year median of 20.48)
GF Value™: €50.29 vs. price of €46.70 (7.1% below fair value)
Industry Position: 208.4% above the Medical Devices & Instruments median (#155 of 816)
No single metric tells the full story. See the STU:61MA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MedCap AB acquires and develops profitable, market-leading niche companies in the Nordic life science industry. It is diversified into two business areas namely Medical technology and Specialist medicines. Medical Technology mainly develops and sells various medical technology products and services. Its Specialist medicines develop and sell medicines within the regulatory classes of registered, extemporaneous and licensed medicines.
80GF Score
Get the complete analysis for STU:61MA
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:61MA has been successfully added to your 
